| 0.776 0.006 (0.79%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.12 | 1-year : | 1.28 |
| Resists | First : | 0.96 | Second : | 1.1 |
| Pivot price | 0.89  |
|||
| Supports | First : | 0.75 | Second : | 0.62 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.91 |
| MA(100) : | 1.02 |
MA(250) : | 1.38 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 11 |
| RSI | RSI(14): 35.4  |
|||
| 52-week | High : | 2.59 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCYX ] has closed above bottom band by 15.9%. Bollinger Bands are 16.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.78 - 0.79 | 0.79 - 0.79 |
| Low: | 0.74 - 0.74 | 0.74 - 0.75 |
| Close: | 0.77 - 0.78 | 0.78 - 0.78 |
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Sat, 17 May 2025
Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely - simplywall.st
Fri, 16 May 2025
SCYNEXIS Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView
Thu, 15 May 2025
Scynexis: Q1 Earnings Snapshot - MySA
Thu, 15 May 2025
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus
Thu, 15 May 2025
SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock - Stock Titan
Tue, 08 Apr 2025
Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 39 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 31.1 (%) |
| Shares Short | 691 (K) |
| Shares Short P.Month | 695 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.45 |
| Profit Margin | 0 % |
| Operating Margin | -824.3 % |
| Return on Assets (ttm) | -21.2 % |
| Return on Equity (ttm) | -33.3 % |
| Qtrly Rev. Growth | -83.1 % |
| Gross Profit (p.s.) | 0.09 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | -0.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -1.77 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 8.07 |
| Price to Cash Flow | -1.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|